Physician profile
Mark I Ignatius
NPI 1073743233
$11,984.14
in general payments reported to CMS, 2019-2025
9 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 91% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,731 · 2020: $657 · 2021: $1,170 · 2022: $658 · 2023: $1,281 · 2024: $1,916 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,768.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $4,147.89 | 2019 | |
| Biotronik Nro, INC. | $3,287.52 | 2024-2025 | Prospera |
| Abbott Laboratories | $2,412.27 | 2019-2024 | Eterna |
| Bioventus LLC | $1,625.69 | 2022-2023 | Stimrouter Implantable Kit |
| Medtronic, INC. | $167.19 | 2023 | Vanta Adaptivestim |
| Boston Scientific Corporation | $160.32 | 2019-2023 | |
| The Cameron-Ehlen Group, INC. | $135.60 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.82 | 2025 | |
| Mallinckrodt Enterprises LLC | $19.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ignatius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.